Compare Stryker Corporation (SYK) vs Verisign, Inc. (VRSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Stryker Corporation vs Verisign, Inc. — how do they compare? Stryker Corporation trades at $277.44 (market cap $105.63B), while Verisign, Inc. trades at $287 (market cap $25.94B). The key difference: Stryker Corporation is far larger — about 4.1× Verisign, Inc.'s market cap, and Stryker Corporation pays the higher dividend (1.28%). Which is the better fit depends on your goals.
| SYK | VRSN | |
|---|---|---|
Market Cap | $105.63B | $25.94B |
Sector | Technology | Technology |
52-Week High | $388.79 | $310.00 |
52-Week Low | $275.39 | $211.49 |
Enterprise Value | $117.10B | $27.25B |
Dividend Yield | 1.28% | 1.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Stryker (SYK) is trading at $276.43, down 8.81% over 24 hours, with a bearish technical signal from moving averages but bullish oscillators. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. Strong fundamentals include a net income margin of 14.43% and ROE of 16.51%, though valuation ratios like a P/E of 28.65 are elevated. Recent news includes a securities fraud investigation announcement and the launch of an FDA-cleared surgical app for Apple Vision Pro.
The outlook for SYK is supported by solid profitability and growth initiatives like acquisitions and product launches, but near-term risks include the fraud investigation and competitive pressures. Analyst consensus is strongly bullish with a $376 price target, suggesting significant upside potential if the company navigates current challenges successfully.
VeriSign (VRSN) trades at $282.20, down 3.38% on the day, with a bearish technical signal despite strong institutional buying interest. The company maintains exceptional profitability with 49.77% net margins and consistent revenue growth, though recent earnings have been mixed with two misses in the last four quarters. A major antitrust lawsuit filed in September 2026 poses significant regulatory risk, while analyst consensus remains bullish with a $328.50 price target representing 16% upside potential.
The stock presents a compelling value proposition given its strong cash flow generation and dominant market position in domain registry services, but faces headwinds from legal challenges and competitive pressures. Current valuation at 30.64 P/E appears reasonable for the quality of earnings, though the negative shareholder equity position warrants monitoring of debt levels. Upside potential exists if the company successfully navigates regulatory challenges and maintains its pricing power.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →About Verisign, Inc.
Verisign is the sole authorized registry for several generic top-level domains, including the widely utilized .com and .net top-level domains. The company operates critical Internet infrastructure to support the domain name system, including operating two of the world's 13 root servers that are used to route Internet traffic. In 2018, the firm sold off its Security Services business, signalling a renewed focus on the core registry business.
Read more on VRSN →
